[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553718":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":23,"locations":10,"responsibleParty":31,"collaborators":33,"id":36,"slug":10,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":41,"sex":42,"minAge":43,"maxAge":10,"enrollmentInfo":44,"targetDuration":47,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":10},{"fullName":5,"class":6},"University of Zurich","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Highlanders living above 2500 m",null,"Highlanders permanently living above 2500 m in the Aksay area in Kyrgyzstan",{"label":13,"type":10,"description":14,"interventionNames":10},"Low altitude control","Healthy lowlanders living below 1000 m.",[16,20],{"name":17,"affiliation":18,"role":19},"Talant M Sooronbaev, Prof. Dr.","National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":22,"role":19},"Silvia Ulrich, Prof. Dr.","University Hospital Zurich, Department of Pulmonology",[24,28],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+41442552220","silvia.ulrich@usz.ch",{"name":29,"role":25,"phone":26,"phoneExt":10,"email":30},"Michael Furian, Prof. Dr.","michael.furian@usz.ch",{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[34],{"name":18,"class":35},"OTHER_GOV","100553718",false,"NCT06489730","HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.","Inclusion Criteria:\n\n* Permanently living \\>2500 m\n* Written informed consent\n\nExclusion Criteria:\n\n* Highlanders who cannot follow the study investigations,\n* Patients with moderate to severe concomitant lung disease (FEV1\\\u003C70% or forced vital capacity \\\u003C70%), severe parenchymal lung disease, heavy smoking \\>20 cigarettes\u002Fday or \\>20 pack-years.\n* Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months\n* Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)",true,"ALL","18 Years",{"count":45,"type":46},120,"ESTIMATED","7 Years","OBSERVATIONAL","The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participate din the study in 2017 to undergo follow-up examinations in 2024, in order to allow comparisons of current results with baseline data from 2017.",[51,52],"High Altitude Pulmonary Hypertension","Sleep Apnea",[54,55,56,57,58],"high altitude illness","pulmonary hypertension","sleep apnea","disease progression","hypoxia","NOT_YET_RECRUITING","2024-06-28",{"date":62,"type":63},"2024-07-08","ACTUAL",{"date":65,"type":46},"2024-07-01",{"date":67,"type":46},"2024-12-31",{"name":5,"class":6}]